Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EG-007 plus lenvatinib and pembrolizumab in advanced endometrial cancer
NCT05106127Phase 2Not yet recruiting
- Sponsor
- Evergreen Therapeutics, Inc.
- Start
- Aug 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of EG-007 in endometrial cancer (EC) (3 arms), sponsored by Evergreen Therapeutics, Inc. Primary endpoints: Adverse Events at 21 days and Tolerability Score at 21 days. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
EG-007
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT05106127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05106127.